Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Rituximab at fixed regimen better for long-term remission: Study

An 18-month fixed-schedule maintenance regimen of rituximab is better at keeping ANCA-associated vasculitis (AAV) in remission for up to seven years than azathioprine or a rituximab regimen tailored to an individual, according to pooled data from the Phase 3 MAINRITSAN program. Doubling the length of this fixed-schedule regimen did…

GPA is most common type of ANCA-associated vasculitis in Italy

Granulomatosis with polyangiitis (GPA) is the most common type of ANCA-associated vasculitis (AAV) in Italy and is linked to worse symptoms and higher mortality and healthcare costs than microscopic polyangiitis (MPA), another common AAV type, a study finds. Using immunosuppressive glucocorticoids was also associated with higher costs…

Lung damage patterns on CT scans may differ by ANCA, AAV types

People with ANCA-associated vasculitis (AAV) may present different lung involvement patterns depending on the type of disease and self-reactive antibodies driving the disease, according to a small study. Given that “the type of pulmonary involvement in AAV is important to predict prognosis and mortality as well as for treatment…

Low dose of corticosteroids as good as high dose for AAV: Study

A low dose of intravenous or into-the-vein methylprednisolone, a corticosteroid, is as safe and effective as a high dose at preserving kidney function and extending survival in people with severe ANCA-associated vasculitis (AAV), a U.K. study found. Given that corticosteroids, a standard AAV treatment, are associated with significant…

Fasenra fares no worse than Nucala at keeping EGPA in remission

AstraZeneca’s Fasenra (benralizumab) — approved for a rare type of asthma — does no worse than Nucala (mepolizumab) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. These are the first findings of the head-to-head Phase 3 MANDARA clinical trial (NCT04157348) that showed the study met its…

Antibody-targeted approach bests plasma exchange in AAV: Study

An approach that removes specific antibodies from a person’s blood is better than a standard, more general blood-cleaning procedure called plasma exchange at clearing the self-reactive antibodies that drive ANCA-associated vasculitis (AAV). That’s according to a small study in China that looked at data from AAV patients with severe…